These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17555466)

  • 21. Kava extracts: safety and risks including rare hepatotoxicity.
    Teschke R; Gaus W; Loew D
    Phytomedicine; 2003; 10(5):440-6. PubMed ID: 12834011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits.
    Teschke R; Qiu SX; Lebot V
    Dig Liver Dis; 2011 Sep; 43(9):676-81. PubMed ID: 21377431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kava hepatotoxicity--a clinical review.
    Teschke R
    Ann Hepatol; 2010; 9(3):251-65. PubMed ID: 20720265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop.
    Thomsen M; Schmidt M
    J Ethnopharmacol; 2021 Mar; 268():113582. PubMed ID: 33189846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum).
    Jhoo JW; Freeman JP; Heinze TM; Moody JD; Schnackenberg LK; Beger RD; Dragull K; Tang CS; Ang CY
    J Agric Food Chem; 2006 Apr; 54(8):3157-62. PubMed ID: 16608246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tradition and toxicity: evidential cultures in the kava safety debate.
    Baker JD
    Soc Stud Sci; 2011 Jun; 41(3):361-84. PubMed ID: 21879526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piper methysticum (kava kava).
    Altern Med Rev; 1998 Dec; 3(6):458-60. PubMed ID: 9855570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study.
    Sarris J; Laporte E; Scholey A; King R; Pipingas A; Schweitzer I; Stough C
    Traffic Inj Prev; 2013; 14(1):13-7. PubMed ID: 23259514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?
    Sarris J; Teschke R; Stough C; Scholey A; Schweitzer I
    Planta Med; 2011 Jan; 77(2):107-10. PubMed ID: 20814850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(47):1065-7. PubMed ID: 12500906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute liver failure after administration of herbal tranquilizer kava-kava (Piper methysticum).
    Brauer RB; Stangl M; Stewart JR; Pfab R; Becker K
    J Clin Psychiatry; 2003 Feb; 64(2):216-8. PubMed ID: 12633134
    [No Abstract]   [Full Text] [Related]  

  • 32. Kava--the unfolding story: report on a work-in-progress.
    Denham A; McIntyre M; Whitehouse J
    J Altern Complement Med; 2002 Jun; 8(3):237-63. PubMed ID: 12165183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver transplantation and the use of KAVA: Case report.
    Becker MW; Lourençone EMS; De Mello AF; Branco A; Filho EMR; Blatt CR; Mallmann CA; Schneider M; Caregnato RCA; Blatt CR
    Phytomedicine; 2019 Mar; 56():21-26. PubMed ID: 30668342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kava kava: examining new reports of toxicity.
    Clouatre DL
    Toxicol Lett; 2004 Apr; 150(1):85-96. PubMed ID: 15068826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration.
    Ulbricht C; Basch E; Boon H; Ernst E; Hammerness P; Sollars D; Tsourounis C; Woods J; Bent S
    Expert Opin Drug Saf; 2005 Jul; 4(4):779-94. PubMed ID: 16011454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of kava for patients with mild anxiety disorders.
    Saeed SA; Bloch RM; Antonacci DJ
    Am Fam Physician; 2008 Aug; 78(4):433-4. PubMed ID: 18756649
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.).
    Anke J; Ramzan I
    J Ethnopharmacol; 2004 Aug; 93(2-3):153-60. PubMed ID: 15234747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kava hepatotoxicity solution: A six-point plan for new kava standardization.
    Teschke R; Sarris J; Lebot V
    Phytomedicine; 2011 Jan; 18(2-3):96-103. PubMed ID: 21112196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kava as a Clinical Nutrient: Promises and Challenges.
    Bian T; Corral P; Wang Y; Botello J; Kingston R; Daniels T; Salloum RG; Johnston E; Huo Z; Lu J; Liu AC; Xing C
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33027883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products?
    Lechtenberg M; Quandt B; Schmidt M; Nahrstedt A
    Pharmazie; 2008 Jan; 63(1):71-4. PubMed ID: 18271308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.